Citigroup Inc Voyager Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 36,978 shares of VYGR stock, worth $213,732. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,978

Previous 20,320 81.98%

Holding current value

$213,732

Previous $160,000 35.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$5.77 - $9.27 $96,116 - $154,419	16,658 Added 81.98%	36,978 $216,000
Q2 2024 Aug 12, 2024	SELL	$7.42 - $10.54 $632,725 - $898,777	-85,273 Reduced 80.76%	20,320 $160,000
Q1 2024 May 10, 2024	BUY	$7.15 - $10.84 $716,644 - $1.09 Million	100,230 Added 1868.92%	105,593 $983,000
Q4 2023 Feb 09, 2024	BUY	$6.28 - $8.81 $33,572 - $47,098	5,346 Added 31447.06%	5,363 $45,000
Q3 2023 Nov 09, 2023	SELL	$7.55 - $11.25 $71,913 - $107,156	-9,525 Reduced 99.82%	17 $0
Q2 2023 Aug 10, 2023	SELL	$6.94 - $13.99 $528,064 - $1.06 Million	-76,090 Reduced 88.86%	9,542 $109,000
Q1 2023 May 11, 2023	BUY	$6.0 - $10.78 $9,594 - $17,237	1,599 Added 1.9%	85,632 $660,000
Q4 2022 Feb 09, 2023	BUY	$4.94 - $6.61 $398,900 - $533,750	80,749 Added 2458.86%	84,033 $512,000
Q3 2022 Nov 10, 2022	BUY	$5.57 - $7.47 $18,291 - $24,531	3,284 New	3,284 $19,000
Q2 2022 Aug 10, 2022	SELL	$4.82 - $10.09 $117,902 - $246,811	-24,461 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.75 - $9.44 $67,267 - $230,911	24,461 New	24,461 $186,000
Q4 2021 Feb 10, 2022	SELL	$2.47 - $5.55 $4,910 - $11,033	-1,988 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$2.63 - $4.12 $5,228 - $8,190	1,988 New	1,988 $5,000

Others Institutions Holding VYGR

# of Institutions

130

Shares Held

34.7M

Call Options Held

39.7K

Put Options Held

34.6K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account